Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅲ Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Ilaprazole (20mg QD) in Adult Patients With Erosive Esophagitis

NCT01509261 is registered in ClinicalTrials.gov with Il-Yang Pharm. Co., Ltd. as lead sponsor.

NCT NCT01509261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01509261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅲ Multi-center, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Ilaprazole (20mg QD) in Adult Patients With Erosive Esophagitis
Lead sponsor
Il-Yang Pharm. Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2010
Completion date
June 30, 2011
Enrollment
292 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

erosive esophagitis, gerd